All KOL Pulse conferences
Post-Conference Intelligence · Apr 25 – Apr 30, 2025

AACR 2025

Chicago, IL — top KOL voices, trial buzz, and themes pulled from verified physician social.
429Physician tweets
186Unique KOLs
954.5KTotal impressions
KOL Voices

Who moved the needle at AACR 2025

Top physician voices ranked by impressions. Institutional / media accounts excluded.

Emerging Themes

What KOLs were talking about

Click any theme to see the top tweets that matched.

NEJM
@nejm
Presented at #AACR25: Neoadjuvant PD-1 blockade with dostarlimab led to organ preservation in a high proportion of patients with early-stage mismatch repair–deficient tumors, with no compromise of surgical options. Full study results: https://t.co/o5tjgLnXm6  @AACR https://t.co/faItAMLuvs
23.6K impressions
Ana I. Velázquez Mañana, MD, M
@anavmanana
Dr. @peters_solange presents SKYSCRAPER-01: tiragolumab + atezolizumab vs. atezo + placebo in 1L PD-L1 high advanced NSCLC As we had seen on prior press-release there is no statistically significant benefit in PFS or OS of adding anti-TIGIT to atezo #LCSM #AACR25 https://t.co/6SvFgFTBZY
18.6K impressions
Stephen V Liu, MD
@stephenvliu
SKYSCRAPER-01 presented at #AACR25 by Dr. @peters_solange: phase III study of first-line atezolizumab + tiragolumab (anti-TIGIT) or placebo in PD-L1 high NSCLC. Some separation of PFS curves but not statistically significant and no difference in OS. https://t.co/3qJg6zuvrV
13.3K impressions
Paolo Tarantino
@ptarantinomd
No significant benefit with co-targeting PDL1 and TIGIT in NSCLC. Though there is an interesting positive trend in all outcomes (PFS, ORR, OS). Additional biomarkers needed to define who benefits. https://t.co/qdkP3dhipD https://t.co/rNkEaAvPrd
7.4K impressions
Nadeem Riaz
@xrtgenomics
🚨Finally! @DrUppaluri presents data from Keynote0689 -- anti-PD1 makes it in locally advanced HNSCC -- approximate 10% EFS benefit from Pembro in surgically managed HNSCC. #aacr25 #hncsm https://t.co/tqiTK75enF
7.3K impressions
Hidehito HORINOUCHI
@hhorinouchi
🆙#AACR25 #LCSM in advance 🔥#CT051 - SKYSCRAPER-01: Tiragolumab + atezo vs placebo + atezo in patients with previously-untreated PD-L1-high, locally advanced unresectable/metastatic NSCLC 🎙️ @peters_solange ✅Phase III ✅NCT04294810 @OncoAlert @AACR https://t.co/EXnglXjHDG https://t.…
6.7K impressions
Ingo Hartung
@hartungingo
Highly significant selection of the first speaker in the opening plenary at #AACR25: @kevansf talking about the impressive progress in targeting KRas with small molecules. Decades of investing into fundamental science now generating first clinical impact. And much more to come… https://t.co/9FTGRXOvF2
55.4K impressions
Ingo Hartung
@hartungingo
Brian Lanman @Amgen opening the first New Drugs on the Horizon session at #AACR25 with panKRas inhibitor AMG410. What an impressive example for structure-based multi-parameter optimization leading to a macrocyclic oral candidate molecule with selectivity over N/H-Ras. @AACR https://t.co/lSCHKagjWi
10.2K impressions
Dr. Ariella Hanker
@ariellahanker
Lots of #KRAS at #AACR25! Incredible to think that Ras was “undruggable” <10yrs ago and now >50 clinical trials! Next, how to tackle resistance? @andrewaguirremd explains diverse resistance mutations and potential combos https://t.co/eWyRboFfiE
8.8K impressions
Anirban Maitra
@aiims1742
Key resistance data in patients with #PancreaticCancer receiving PanKRASi Daraxonrasib. By @andrewaguirremd #AACR25 - Amplification of mutant KRAS allele under selection pressure in 1/3rd pts on progression. - No secondary KRAS alterations - Multiple alterations in RAS pathway https://t.co/emfGlsC6Lk
5.9K impressions
Dr. Ariella Hanker
@ariellahanker
Now at #AACR25 plenary: @kevansf explains how to overcome the “undruggable” nature of #KRAS. ❎can’t block GTP binding because of picomolar affinity ❎efforts to block membrane localization failed due to alternative prenylation ✅potential for blocking downstream effectors https://t.co/7upG1mb8H0
4.0K impressions
CrozrX
@crozrx
#AACR25 Preliminary safety and antitumor activity of zoldonrasib (RMC-9805), an oral, RAS(ON) G12D-selective, tri-complex inhibitor in patients with KRAS G12D non-small cell lung cancer (NSCLC) from a phase 1 study in advanced solid tumors https://t.co/sZTCawtLOB https://t.co/U7uSF9karK
3.6K impressions
Ingo Hartung
@hartungingo
Another excellent educational talk about ADC design aspects at #AACR25 by Rafaele Colombo. Linking payload potency & linker stability to clinical observations. Well, it remains complex to deduce generalizable design principles. Understanding payload fate is crucial. https://t.co/a9IJDY5PHc
25.5K impressions
Paolo Tarantino
@ptarantinomd
Debunking 2 myths: 🚫More potent payload ≠ better ADC 🚫More stable ≠ better ADC Highly potent payloads have proven to be too toxic. Highly stable ADCs have been found associated with unexpected side effects (eg. ocular). Balance is key. Terrific presentation by @raffcolo https://t.co/GQ8z6j0xxr https://t.co/CcOazpctHB
14.3K impressions
Raffaele Colombo
@raffcolo
Well, my #AACR25 slide with the first dual-payload ADC in the clinic didn't last long... IBI3020, a CEACAM5 dual-payload ADC is now lined up for clinical development (CTR20251512)! https://t.co/FrrEmj1WHv
9.0K impressions
Stephen V Liu, MD
@stephenvliu
Exciting update on trastuzumab rezetecan (SHR-A1811, HER2 ADC) in #HER2 mutant NSCLC from #AACR25. All pts had prior chemo-IO: RR 74.5%, TTR 1.4m, DOR 9.8m, PFS 11.5m, 1y OS rate 88%. First-line phase III trial underway vs chemo-IO. https://t.co/ZnFaFujhsi
4.6K impressions
LARVOL
@larvol
Here are the clinical stage Antibody-drug conjugates (ADCs) assets data to be presented at the @AACR 2025. #LARVOL #AACR25 #CancerResearch #Oncology #AntibodyDrugConjugates #ADCs #CancerData | @Larvol Reach out to some o…
4.0K impressions
Yakup Ergün
@dr_yakupergun
T-DXd vs. Zongertinib in HER2-Mutant NSCLC: Or Sequential Use? Efficacy: Zongertinib➡️71% ORR, 14.1-mo response duration, 12.4-mo PFS. 48% ORR post-T-DXd! T-DXd➡️55% ORR, 9.3-mo response, 8.2-mo PFS, 17.8-mo OS. 💥Zongertinib has higher ORR/PFS; T-DXd provides OS data. https://t.co/GGq5P2joUL
2.8K impressions
NEJM
@nejm
Presented at #AACR25: Among patients with tumors harboring tyrosine kinase domain mutations who received zongertinib (a selective inhibitor of the HER2 tyrosine kinase), 71% had a response, and median progression-free survival was 12.4 months. Full study results: https://t.co/QEsXsFxnkP
33.9K impressions
Oncology Brothers
@oncbrothers
#AACR25 highlights #CommunityOnc: 1. #KN689: PeriOP/PostOP Pembro in H&N 2. NeoAdj Dostarlimab in dMMR solid tumors 3. #BeamionLung1: Zongertinib in HER2 NSCLC 4. **Bonus from #AUA25 #SunRISE1 in NMIBC #OncTwitter #MedTwit…
11.2K impressions
Rami Manochakian MD, FASCO Can
@rmanochakian
🔥🚨@OncoAlert Hot Off The Press. Just published @NEJM Results of: ⭐️ #Beamion LUNG-1 phase 1a–1b of: #Zongertinib (#Oral, irreversible, HER2 #TKI) in previously treated #Patients with advanced #HER2-mutant non-small- cell #Lung…
5.7K impressions
Elizabeth McKenna
@elizsmckenna
ICYMI in @CD_AACR ahead of today's big clinical plenary at #AACR25 - the preclinical characterization and early clinical proof-of-concept of zongertinib, an irreversible HER2 TKI that spares EGFR signaling and has activity in HER2-driven cancers https://t.co/8HrrIGaH7c https://t.co/AFqbTgKAim
5.7K impressions
Stephen V Liu, MD
@stephenvliu
Zongertinib in #HER2 NSCLC simultaneous publication @NEJM with #AACR25 presentation by Dr. John Heymach. In previously treated HER2 TKD mt NSCLC, RR 71%, duration of response 14.1m, mPFS 12.4m. G3 AEs in only 17% - diarrhea in 56% of pts but only 1 single case of G3 or higher. https://t.co/ZzSoeixFCy
5.3K impressions
Stephen V Liu, MD
@stephenvliu
Exciting update on trastuzumab rezetecan (SHR-A1811, HER2 ADC) in #HER2 mutant NSCLC from #AACR25. All pts had prior chemo-IO: RR 74.5%, TTR 1.4m, DOR 9.8m, PFS 11.5m, 1y OS rate 88%. First-line phase III trial underway vs chemo-IO. https://t.co/ZnFaFujhsi
4.6K impressions
Yakup Ergün
@dr_yakupergun
Nonoperative Management of Mismatch Repair–Deficient Tumors Stage 1-3, 6-mo dostarlimab cCR All ➡️ 84 pts (82%) Rectal➡️💯% Other➡️65% Almost all patients with CCR did not undergo surgery 2y RFS➡️92% 💥ctDNA correlated with response #AACR25 https://t.co/IYdB5Z6oEc https://t.co/ZgMqGxdJqy
9.2K impressions
Memorial Sloan Kettering Cance
@mskcancercenter
In her plenary session at #AACR25, @YJanjigianMD presented important findings from her study on adjuvant #immunotherapy, which directed by ctDNA status, can clear minimal residual disease in patients with DNA mismatch repair-deficient solid cancers. @AACR https://t.co/ap7X6wL0El
4.3K impressions
Personalis, Inc.
@personalisinc
🚨 BIG NEWS! 🚨 Our NeXT Personal® ultrasensitive ctDNA assay will be featured at #AACR25 in Chicago! 🌟 Two oral presentations: 🔬 Dr. @emma_titmuss presents #VICTORI study (colorectal #MRD) - Apr 28, 3:35PM, S105 🧬 Prof. @CharlesSwanton shares #TRACERx results - Apr 28, htt…
2.0K impressions
UChicagoCancerCenter
@uccancercenter
Robert Cameron from the @MarinaGarassino Lab presented a poster at AACR this morning on the association between tissue genomic alterations and ctDNA shedding in NSCLC. #AACR25 https://t.co/Q4VwGVvkEk
1.8K impressions
Dr Amol Akhade
@suyogcancer
New KRASG12C inhibitor D3S-001 shines! (Nature Medicine, 2025) Results: NSCLC (naive): 66.7% ORR CRC (naive): 88.9% ORR PDAC: 75% ORR Post-G12Ci NSCLC: 30% ORR ✅ No DLTs ✅ Good CNS activity ✅ High ctDNA clearance Next-gen G12C inhibitor to watch! #OncoTwitter #KRAS #LungCancer
1.6K impressions
Abner Antonio Murray, MD PhD
@dominicandoc2
🚨 NEW at #AACR25: First-in-human mRNA vaccine combo for frail #NSCLC! 🚨 🧬 BNT116 (targets 6 tumor antigens) + cemiplimab (PD-1) 🔹 ORR 45%, DCR 75% 🔹 ≥50% ctDNA clearance linked to longer responses 🔹 Acceptable safety, mild flu-like AEs Hope for patients unfit for chemo. https://t.co/gxYudTlsJe
1.5K impressions
Memorial Sloan Kettering Cance
@mskcancercenter
In her plenary session at #AACR25, @YJanjigianMD presented important findings from her study on adjuvant #immunotherapy, which directed by ctDNA status, can clear minimal residual disease in patients with DNA mismatch repair-deficient solid cancers. @AACR https://t.co/ap7X6wL0El
4.3K impressions
Personalis, Inc.
@personalisinc
🚨 BIG NEWS! 🚨 Our NeXT Personal® ultrasensitive ctDNA assay will be featured at #AACR25 in Chicago! 🌟 Two oral presentations: 🔬 Dr. @emma_titmuss presents #VICTORI study (colorectal #MRD) - Apr 28, 3:35PM, S105 🧬 Prof. @CharlesSwanton shares #TRACERx results - Apr 28, htt…
2.0K impressions
Abner Antonio Murray, MD PhD
@dominicandoc2
🚨 Major advance in #HNSCC #MRD detection at #AACR25! Using a tumor-informed #ctDNA assay tracking 1000s of SNVs, researchers achieved: 🧬 100% sensitivity pre-treatment 🧪 87% sensitivity post-induction, 50% post-treatment 🛡️ 100% specificity both times 🔎 Every ctDNA+ patient https://t.co/b6T…
964 impressions
Al Garfall
@algarfall
Very nice study by @SusanBal9 & @End_myeloma demonstrating marked reduction in MRD burden after auto SCT in patients receiving quad induction for myeloma #mmsm https://t.co/aESjm7d2Zy
688 impressions
CRUKCOLcentre
@crukcolcentre
Packed auditorium hearing Prof @CharlesSwanton #CRUKFunded City of London Centre leadership speaking about latest from TracerX on ultrasensitive MRD detection at #AACR25. https://t.co/ALnfvM1gi5
657 impressions
Personalis, Inc.
@personalisinc
We have exciting new data to present during the American Association for Cancer Research® (AACR) Annual Meeting 2025! Check out the following during #AACR25. Stop by our booth (# 2336) to learn more. #PrecisionOncology #Biomarkers #LiquidBiopsy #MRD #WGS …
624 impressions
Anant Madabhushi
@anantm
🚨 New preprint! AI-assessed tumor-stroma proportion (TSPauto) outperforms KELIM in predicting treatment response & survival in epithelial ovarian cancer. 🧠 >94% concordance w/ pathologists 📈 Prognostic before treatment begins 📄 Read: https://t.co/O3cirPaYYG #DigitalPathology https://t.co/tqSxZRxrv8
1.7K impressions
Tempus
@tempusai
Join us at our #AACR25 Exhibitor Spotlight Theater as we explore the transformative role of #AI in oncology research and the development of new treatments. Speakers Robert Shoemaker, Ph.D., Ryan Fukushima and Jonathan Ozeran will share how machine learning and real-world data are https://t.co/mJnGwEHaex
1.6K impressions
AACR
@aacr
.@MCR_AACR editor-in-chief Massimo Loda, chair of the AACR Pathology in Cancer Research Working Group, moderated a Town Hall Meeting that addressed "How AI Will Impact the Future of Pathology" yesterday at #AACR25. https://t.co/hLvxgLmMUk
1.3K impressions
Moffitt Cancer Center
@moffittnews
At #AACR25, Sabeen Ahmed showcased a cutting-edge #AI tool that combines imaging and clinical data to improve early detection of cancer cachexia. These findings highlight how machine learning can transform cancer care. Read more: https://t.co/xsUYnYD0vf #MoffittAACR25 https://t.co/TUEheoE21G
912 impressions
Moffitt Cancer Center
@moffittnews
During #AACR25, Ghulam Rasool, PhD (@Gxrasool) joined us to discuss PARADIGM, a powerful multimodal #AI framework using foundation models and graph neural networks to predict overall survival. See how AI is transforming cancer prognosis! Read more: https://t.co/MP8l7ieJXI https://t.co/VvRLN4MOV7
534 impressions
Radiology: Artificial Intellig
@radiology_ai
Testing a commercial #AI system for #BreastCancer detection at the BC #Cancer Breast Screening Program https://t.co/MzpxBrpYaw @AACR #AACR25 #AACR2025 #cancer #OncoRad #oncology https://t.co/1liPMJGRpO
482 impressions
Tian Zhang, MD, MHS
@tiansterzhang
Plenary session with @MarcelaMaus @MGHCancerCenter on future CAR-T cells — setting vision toward personalized, patient centered approaches to find the right CARTs. #AACR25 @OncoAlert https://t.co/ZxD80vtahN
2.5K impressions
Sandip Patel MD FASCO
@pateloncology
Looking to be an outstanding @AACR Clinical Trials Plenary session on Bispecifics and T cell engagers on Tues 4/29 10:15am CST featuring @wolchokj @hoperugo @jasonlukemd and other outstanding faculty. I am excited to be discussing CART in thyroid cancer in this great program https://t.co/qOCwliUjIg
1.8K impressions
Moffitt Cancer Center
@moffittnews
At the #AACR25 plenary on Innovative Technologies, Marcela V. Maus, MD, PhD (@MassGenBrigham), emphasizes the need for fit-for-purpose CAR-T cells—asking how we can reduce toxicity, boost efficacy by modulating IFNγ and prioritize the most promising constructs for clinical https://t.co/VPoLviRwpl
832 impressions
MD Anderson Cancer Center
@mdandersonnews
New CAR T cell therapy Phase I trial demonstrates lasting responses in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors, our Dr. Samer Srour shared at #AACR25. Learn more: https://t.co/XDoNttOeMw @AACR #EndCancer https://t.co/rBoNptl9q6
596 impressions
Dr Timos Papagatsias
@_timos_
🚀 #AACR25 is serving breakthroughs: CAR-T vs Blina 🔄, trispecific ADCs, ctDNA-driven trials & AI that nails cancer subtypes with 95 % spec! Precision oncology is moving fast—are you ready? Grab #LucidQuest's preview report https://t.co/nuKEluD31K 🔬 #CancerResearch @AACR
70 impressions
Mass General Brigham Research
@mgbresearchnews
@MarcelaMaus at #AACR25 this morning highlights promising translational efforts that might be able to “drive” CAR T-cell therapies toward success in more cancer types. Read more: https://t.co/mWqqrM8xNp https://t.co/lH6jQZSEeD
18 impressions
Top Tweets

The 10 tweets that defined AACR 2025

Physician voices only, ranked by impressions. Click any card to open the original on X.

Andrea Necchi
@andreanecchi
#1
#SURE02 interim results will be disclosed at #ASCO25 #RapidOral session The trial provides SG-Pembro > bladder sparing for cCR > maintenance pembro to pts with MIBC Interim cCR survival and biomarker data will be presented @SanRaffaeleMI @MyUniSR @Veracyte @FoundationAT…
60.8K impressions
Ingo Hartung
@hartungingo
#2
Highly significant selection of the first speaker in the opening plenary at #AACR25: @kevansf talking about the impressive progress in targeting KRas with small molecules. Decades of investing into fundamental science now generating first clinical impact. And much more to come… https://t.co/9FTGRXOvF2
55.4K impressions
𝐉𝐨𝐡𝐧-𝐖𝐢𝐥𝐥𝐢𝐚𝐦 𝐒𝐢𝐝𝐡𝐨𝐦, 𝐌𝐃, 𝐏𝐡𝐃
@john_will_i_am
#3
LLMs revolutionized NLP—now we’re using them to create intricate mutational fingerprints in cancer. Tomorrow, I will be presenting the first foundation model of somatic variants in oncology using dual-attention transformers that treat variants as words whose meaning emerges https://t.co/D3a0uwrujX
51.2K impressions
Ingo Hartung
@hartungingo
#4
Another excellent educational talk about ADC design aspects at #AACR25 by Rafaele Colombo. Linking payload potency & linker stability to clinical observations. Well, it remains complex to deduce generalizable design principles. Understanding payload fate is crucial. https://t.co/a9IJDY5PHc
25.5K impressions
Ana I. Velázquez Mañana, MD, M
@anavmanana
#5
Dr. @peters_solange presents SKYSCRAPER-01: tiragolumab + atezolizumab vs. atezo + placebo in 1L PD-L1 high advanced NSCLC As we had seen on prior press-release there is no statistically significant benefit in PFS or OS of adding anti-TIGIT to atezo #LCSM #AACR25 https://t.co/6SvFgFTBZY
18.6K impressions
Michael Torres
@mykalt45
#6
#AACR25 preview – a surge in dual-payload conjugates https://t.co/LFJvFV7Yln Worth a re-read…I’m very curious to see what folks have…Top1i + Tubulin isn’t the way to go in our view. We’ve seen antagonism or simply no benefit adding Top1i to MMAE as an example. Hope folks show
18.5K impressions
Paolo Tarantino
@ptarantinomd
#7
A surge in dual-payload conjugates 🎯 💣 💣 List of dual-payload ADCs to be presented at #AACR25: https://t.co/DKCi6zT08a https://t.co/6yNCQUGuSR
17.9K impressions
Jennifer Buell
@jbuell01
#8
At #AACR25, the always insightful and provocative Dr. @MarcelaMaus presents unpublished data: IFN-γ/IFN-γR KO CAR-Ts expand and persist better. As genetic modulations evolve, patients—not models—should drive CAR selection. Living medicines are here. Collaboration is key. We need https://t.co/selpyPX0R0
14.4K impressions
Paolo Tarantino
@ptarantinomd
#9
Debunking 2 myths: 🚫More potent payload ≠ better ADC 🚫More stable ≠ better ADC Highly potent payloads have proven to be too toxic. Highly stable ADCs have been found associated with unexpected side effects (eg. ocular). Balance is key. Terrific presentation by @raffcolo https://t.co/GQ8z6j0xxr https://t.co/CcOazpctHB
14.3K impressions
Stephen V Liu, MD
@stephenvliu
#10
SKYSCRAPER-01 presented at #AACR25 by Dr. @peters_solange: phase III study of first-line atezolizumab + tiragolumab (anti-TIGIT) or placebo in PD-L1 high NSCLC. Some separation of PFS curves but not statistically significant and no difference in OS. https://t.co/3qJg6zuvrV
13.3K impressions
← Back to all conferences